



Early View

Back to basics

How to build a lung: latest advances and emerging themes in lung bioengineering

Martina M De Santis, Deniz A Bölükbas, Sandra Lindstedt, Darcy E Wagner

Please cite this article as: De Santis MM, Bölükbas DA, Lindstedt S, *et al.* How to build a lung: latest advances and emerging themes in lung bioengineering. *Eur Respir J* 2018; in press (<https://doi.org/10.1183/13993003.01355-2016>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©ERS 2018

Title

How to build a lung: latest advances and emerging themes in lung bioengineering

Authors

Martina M De Santis^{1,2,3}, Deniz A Bölükbas^{1,3}, Sandra Lindstedt^{4,5}, Darcy E Wagner^{1,2,3,4}

Author's Contributions

All authors have written, edited, and approved the final manuscript.

Affiliation

¹ Lund University, Department of Experimental Medical Sciences, Lung Bioengineering and Regeneration, Lund, Sweden

² Helmholtz Zentrum Munich, Comprehensive Pneumology Center (CPC), Lung Repair and Regeneration (LRR), Member of the German Center for Lung Research (DZL), Munich, Germany

³ Stem Cell Centre, Lund University, Lund, Sweden

⁴ Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden

⁵ Department of Cardiothoracic Surgery, Heart and Lung Transplantation, Lund University Hospital, Lund, Sweden

***Corresponding Author**

Darcy E Wagner, PhD

Lund University

Department of Experimental Medical Sciences, C12 BMC, Lund, Sweden

Email: darcy.wagner@med.lu.se

Phone:(+46) 46 222 08 39

Take home message

Bioengineering lung tissue shows promise but major challenges must be overcome to advance technologies to the clinic.

Abstract

Chronic respiratory diseases remain a major cause of morbidity and mortality worldwide. The only option at end-stage disease is lung transplantation, but there are not enough donor lungs to meet clinical demand. Alternative options to increase tissue availability for lung transplantation are urgently required to close the gap on this unmet clinical need. A growing number of tissue engineering approaches are exploring the potential to generate lung tissue *ex vivo* for transplantation. Both biologically derived and manufactured scaffolds seeded with cells and grown *ex vivo* have been explored in pre-clinical studies, with the eventual goal of generating functional pulmonary tissue for transplantation. Recently, there have been significant efforts to scale-up cell culture methods to generate adequate cell numbers for human scale bioengineering approaches. Concomitantly, there have been exciting efforts in designing bioreactors which allow for appropriate cell seeding and development of functional lung tissue over time. This review aims to present the current state-of-the-art progress for each of the areas above and to discuss promising new ideas within the field of lung bioengineering.

Novel ideas and hypothesis

The lung is a highly complex and dynamic organ comprised of a number of different cell types with distinct functions. Bioengineering lung tissue *ex vivo* for transplantation is an area receiving increased attention and could address the shortage of donor organs. Current approaches being explored in pre-clinical studies utilize biologically derived or synthetic scaffolds which are seeded with autologous cells from the eventual transplant recipient. Both synthetic and biologically derived scaffolds have distinct advantages and disadvantages. Hybrid scaffolds combining biologically derived and synthetic scaffolds may be a novel approach to limit the disadvantages observed with either synthetic or biologically derived scaffolds alone. A variety of different technologies have been developed to help generate tissue engineering scaffolds for lung such as decellularisation for biological scaffolds and advanced manufacturing processes for producing synthetic scaffolds, such as casting, electrospinning, cryogelation, and microfabrication techniques. In this review, we aim to discuss recent advances and emerging themes in lung tissue engineering and the major challenges which need to be overcome to advance this approach closer to the clinic.

Introduction

Respiratory diseases are the third leading cause of death worldwide and are predicted to continue to increase over the coming years. The overall cost of respiratory disease in the EU amounts to more than €380 billion annually [1]. Currently, the only option for end stage respiratory disease is lung transplantation. Approximately 2000 lung transplants occur annually in Europe [2], with equal or more patients awaiting transplantation. Transplant efficacy remains a significant clinical issue as transplant rejection rates are high and complications can arise due to the required immunosuppressive drugs; 5-year survival is only 50% [3]. Alternative options to increase available tissue for lung transplantation are necessary to close the gap on this unmet clinical need. In addition to the use of lungs donated from circulatory death (DCD) donors and continued development and improvements in *ex vivo* preservation and *ex vivo* lung perfusion (EVLP) techniques attempting to maximize the number of donor lungs suitable for transplantation [4-9], an exciting new area of research focuses on generating lung tissue *ex vivo*. Current approaches being explored for lung tissue engineering utilize a biologically derived or synthetic scaffold which is seeded with cells and cultured *ex vivo* with the eventual goal of generating functional pulmonary tissue for transplantation. Ideally, cells could be sourced from the transplant recipient and thus are conceptualized to reduce the long-term requirements for immunosuppressive drugs and the risk for rejection. Thus, bioengineered lung tissue could help to increase the amount of lung tissue available for transplantation and has the potential to offer benefits over allogeneic transplantation. However, a number of advances still need to be made to translate this concept into the clinic.

Manufacturing of Lung Scaffolds

The lung is a complex organ with at least 40 different resident cell types [10], all of which are necessary for optimal functioning. These cells reside on and within an extracellular matrix (ECM)

comprised of different regional combinations of ECM proteins and glycosaminoglycans (GAGs) (e.g. proteoglycans and hyaluronan) which act together as a scaffold to not only provide structure but also to help direct repair and regeneration following injury [11]. Langer and Vacanti first described tissue engineering approaches, whereby cells are combined with a matrix made of natural or synthetic materials and grown *ex vivo*, followed by transplantation (**Figure 1**) [12]. Several case reports and clinical trials of tissue engineered products have since then demonstrated the feasibility of pursuing these technologies in the clinic [13, 14]. While there were no attempts at generating pulmonary tissue *ex vivo* when tissue engineering was first described, most current approaches have adopted this paradigm. Despite the fact that lung tissue engineering approaches have historically lagged behind those of other fields, there have been exciting recent advances with both natural materials and synthetic materials.

Acellular Lung Scaffolds

Scaffold Source and Effects of Processing, Storage and Sterilization

Acellular (biologic) lung scaffolds have emerged as possible scaffold materials for *ex vivo* lung tissue engineering in recent years. In this approach, acellular scaffolds are obtained by removing the cells from native lung tissue via a method called decellularisation. Ultimately, the goal of any decellularisation protocol is to remove the cellular material without adversely affecting the resulting macroscopic acellular scaffold structure and ECM composition, mechanical integrity or biological activity of the ECM components [15-17]. The acellular lung could then ideally be recellularised with autologous cells or alternatively, an allogeneic source. A major advantage of acellular lung scaffolds is that they mostly retain the complex structure and macro- and micro-architecture of the native lung tissue, which cannot be generated using any known manufacturing techniques. The majority of ECM components have been found to be retained in the acellular tissue following decellularisation [18-20], although the degree to which these components are retained in their native orientation has not been studied

extensively. The retention of ECM components, as well as their organisation, is likely vital for the function of the eventual engineered tissue.

The ECM is one of the major constituents of the microenvironment known to direct cell behaviour such as migration, proliferation and differentiation [18, 21, 22]. Acellular tissue scaffolds have been shown to retain bioactive properties and a certain degree of tissue specificity [19, 23]. Recent studies have shown that aged scaffolds and those derived from lung disease can drive the acquisition of deranged cellular phenotypes in cells from normal patients [21, 24-28]. Thus, human scaffolds from aged patients or those with pre-existing lung diseases are likely not the ideal sources for lung tissue engineering scaffolds.

Interestingly, a recent study indicated that scaffolds derived from early post-natal human lungs support enhanced re-epithelialisation as compared to those derived from adult lungs [29]. While post-natal lungs could be used to generate scaffolds for neonates, a major concern with using neonate lungs for adult lung tissue engineering is the size mismatch. A study which investigated the outcome of lung transplantation from size mismatched donors and recipients found that undersized lungs received higher tidal volumes because of differences between the weight of donors and recipients [30, 31]. Additionally, lung transplants using undersized lungs are associated with an increased risk of primary graft dysfunction [32]. While it is unclear how or if lungs from neonates might be used for adult lung tissue engineering schemes, the information gained from these studies may lead to new ideas in utilising scaffolds derived from adult donors.

When considering sources for clinical grade scaffold materials, the donor tissue does not necessarily need to be of human origin. Lungs from anatomically similar species, such as porcine or non-human primates, may potentially provide a more uniform donor source, with less limitations than human sources [19, 25, 33-36]. The use of non-human primate lungs has been restricted to preclinical models of bioengineering, and there are ethical concerns with using non-human primate as a source of

acellular scaffolds. Thus, porcine lungs have first emerged as a potential option due to the use of other porcine tissues in xenotransplantation. However, several species- and tissue-specific properties have been identified to date in porcine lungs, which may prove challenging for translation of xenogeneic lung scaffolds recellularised with human cells. Pleural blebs (cystic spaces) have been shown by us and others to arise during the decellularisation process, which may affect the ventilation mechanics of the lung, ultimately compromising the function of the lung if transplanted [24, 34] and if ruptured would lead to pneumothorax (collapsed lung). Furthermore, the extent to which porcine lungs have collateral ventilation is limited as compared to humans. While a variety of cell types have been shown to adhere to porcine scaffolds [24, 25, 34, 36], human derived endothelial cells were found to attach to porcine derived scaffolds at a lower rate as compared to human or primate-derived scaffolds [37], but the reasons for this remain unknown. Residual, cell-associated xenogeneic proteins known to cause negative immunogenic responses in humans have been identified in scaffolds from porcine lungs which are decellularised according to current criteria [18, 25], thus indicating that removal of immunogenic proteins either through transgenic approaches or through post-decellularisation treatments might be necessary.

Moreover, there are several analyses from human cohorts of transplantation that indicate the importance of size matching between donor and recipient [38]. In the case of porcine lungs, the airways and vasculature are often smaller than in human lungs. Surgically anastomosing a porcine lung to a human recipient, especially with regard to the bronchus, will be challenging and a donor recipient mismatch is likely to occur which can lead to death. The lower pulmonary lobes of porcine lungs are shaped after the pig's body because it is a quadruped. The lower pulmonary lobes therefore have a pointed shape and the lung ligaments are significantly more pronounced than in humans. Therefore, basal atelectasis of the lower lobes of the lung may occur if it is transplanted to a human and hence there is an increased risk of infection. The lower pulmonary lobes could be resected at the time of

transplantation, but it is unclear if this would be optimal. Some transplant centres carry out lung resections at the time of transplantation to make the lung fit better into the thoracic cavity. However, some transplant centres are negative towards this approach because of the risk of air leakage from the lung postoperatively. In addition to the major anatomical differences, the risk of cross-species transmission of porcine endogenous retroviruses (PERVs) has impeded the clinical application of xenogeneic tissues [39]. To date, there has been no formal study of the removal or retention of zoonoses, including PERVs, in xenogeneic decellularised scaffolds and thus the danger of disease transmission across species remains unknown [37]. Thus, adult human lungs which narrowly miss the criteria for transplantation and cannot be improved using EVLP technology [6, 40-43], may be viewed as the most likely candidates as a source of scaffolds for a clinical grade lung tissue engineering scheme.

Storage or sterilisation of potential acellular scaffolds for lung tissue engineering have been found to significantly impact both the structure and residual protein content. Moreover, the ability of different cell types to survive and proliferate following inoculation has also been shown to be influenced by the conditions of storage and sterilisation of acellular scaffolds [44]. To date, the majority of acellular lungs have been sterilised using peracetic acid (PAA) which can, however, result in ECM degradation [45, 46]. A recent report described the use of supercritical carbon dioxide (ScCO₂) for sterilising acellular lung scaffolds which does not induce degradation of the ECM [47]. Excellent progress has been made in techniques which could be compatible with good manufacturing practice (GMP) [48]. Interestingly, despite the establishment of some baseline criteria, commercially available scaffolds for other tissues from different companies can have different responses in the same model of *in vivo* injury [49]. It is clear that defining optimal criteria and endpoints regarding the scaffold source and processing of acellular scaffolds will be important in future studies (see **Table 1b**).

Decellularisation Techniques

Common methods to decellularise lungs include different combinations of physical, ionic, chemical and enzymatic methods [15]. Detergent-based perfusion has been most prevalently utilised to generate acellular lung scaffolds. Commonly used detergents include Triton X-100, sodium deoxycholate (SDC), sodium dodecyl sulfate (SDS), and 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), which are used with or without hypertonic sodium chloride and DNase and/or RNase solutions. The concentration and volume of detergents used varies between different protocols and species [21, 23, 24, 26, 34, 35, 37, 50-53]. Solutions may be perfused through the vasculature or both the airways and vasculature. The variation between different protocols has resulted in apparent histologic differences of the decellularised lungs and in content of both ECM and other retained proteins [52, 54, 55]. It remains unclear how differences in lung decellularisation protocols might affect recellularisation and regeneration or potential immunogenicity of the implanted scaffold [56, 57]. The majority of laboratories decellularising tissue utilise the criteria set forth by Crapo et al. which includes absence of visible cellular or nuclear material on histological examination, less than 50 ng dsDNA per 1 mg of dry weight of the ECM scaffold, and remnant DNA shorter than 200 bp [18]. However, these are minimal criteria which do not take into account cytocompatibility (*e.g.* effects of residual decellularising agents), sterility, composition, and mechanical properties of the acellular scaffold [58, 59]. ECM composition and mechanical properties are regionally specific and retention of these differences may be important for recellularisation leading to functional tissue.

Recellularisation and Pre-Clinical Transplantation Models

A variety of different cell types have been successfully used in recellularisation of acellular scaffolds, including embryonic, induced pluripotent stem (iPS) cells and endogenous lung progenitor cells. Efficient differentiation of pluripotent cells to proximal and distal lung epithelial cells remains a

challenging task, but there has been exciting recent progress in deriving distal epithelial progenitor cells and multi-layered epithelium from iPS and murine embryonic stem cells [52, 53, 60-67].

Differentiation of pluripotent stem cells into proximal or distal lung epithelial cells requires growth factors known to be sequestered by the lung ECM [68]. Thus retention of ECM components and their associated growth factors in decellularised lung scaffolds may be critical for optimal recellularisation with regional specificity. The ability of the reseeded cells to survive, proliferate and differentiate is important for assessing both short and long-term cytocompatibility of the scaffold. Further understanding of how the remaining ECM and residual protein composition may affect seeded cell types over time will be an important area of future studies (see **Table 1b**).

Important proof of concept studies have shown that acellular lung scaffolds can be recellularised with either single cell suspensions from fetal lung homogenates and re-endothelialised with immortalised endothelial cell lines or iPS-derived endothelium and epithelium [69] for transplantation. When transplanted into rats, recellularised lung scaffolds were shown to briefly function *in vivo* [50, 53, 70, 71] and more recently acellular porcine scaffolds recellularised with human cells in scaled up porcine studies [36]. However, transplanted lungs were oedematous with regions of collapsed architecture, indicating that long-term functional lung regeneration has yet to be achieved. Nonetheless, these studies encourage the feasibility of this approach.

The Goldilocks Principle of the Remaining Proteins: 'too much', 'too little', and Finding 'just right'

The purpose of most decellularisation processes is to remove the cellular and immunogenic material from the scaffold, while retaining the ECM proteins and structure. Yet, as mass spectrometry proteomics have rapidly improved to characterise the composition of acellular scaffolds, it has become increasingly evident that large amounts of non-matrisome proteins (cytoskeletal elements and cell-associated proteins) are retained in the scaffold following decellularisation [21, 24]. The presence of

non-matrisome proteins has been observed across different tissues, species, and techniques used in different laboratories [52, 66, 72]. The impact of these residual proteins and other cell-derived components on reseeded cells and their potential immunogenicity have been relatively unexplored for lung tissue engineering. It remains unclear if a) decellularisation protocols which are more aggressive and remove more components or b) protocols which are less aggressive but retain more components will be more beneficial in supporting functional regeneration. Residual proteins have been shown in other tissues to play a significant role in regulating cell behaviour of reseeded cells and on immune cell infiltrates once implanted [73]. Furthermore, the clinical heterogeneity observed between individual healthy patients may make defining minimal criteria challenging [24]. Ultimately, improving our understanding of the composition of decellularised scaffolds and tying these to biological outcomes is an important future direction for the field. **Table 1a** summarizes some of the most important studies to date which have led to advances in using acellular scaffolds for lung tissue engineering.

Artificial lung scaffolds

Although acellular scaffolds show promise in the field of lung bioengineering, the heterogeneity of human lung-derived acellular scaffolds and potential xenogeneic issues make this approach challenging to scale up in a reproducible and controllable manner [21]. An alternative to acellular scaffolds could be artificial (or manufactured) scaffolds. Both synthetic and natural polymers can be used in these approaches and a variety of materials have already been explored for tracheal, bronchial and parenchymal lung tissue engineering (see **Figure 2** and **Table 1a for significant advances**). Artificial scaffolds for tracheas have been more heavily investigated due to the trachea's simpler, tubular structure [74-80]. Many of the materials used to generate scaffolds for pre-clinical studies for large airways are synthetic polymers such as polyhedral oligomeric silsesquioxane poly(carbonate-urea) urethane (POSS-PCU) [74], polyglycolic acid (PGA), pluronic F-127 [81] and polylactic-coglycolic acid

(PLGA) [82], which are all cytocompatible polymers with mechanical properties in the range needed for tracheal tissue engineering. While these materials can be manufactured with good precision and can be processed to have improved storage stability, most lack the necessary biological properties such as native integrin binding sites and bioactive cues for cellular attachment, proliferation and differentiation. It is currently unknown what motifs will need to be added to these scaffolds to support functional regeneration. However, it has been shown that cell seeding and graft coverage can be enhanced by simply modifying the surface of the polymer used in the scaffold such as providing cell attachment sites by increasing surface porosity [74] and/or incorporating individual ECM components [75].

On the contrary, parenchymal lung tissue has a more complex 3D structure and requires thin boundaries and interconnected pores for efficient gas exchange [83]. Due to the difficulty associated with manufacturing a scaffold with geometrical parameters suitable for parenchymal lung tissue, there have been limited reports. To date, potential scaffolds for parenchymal tissue engineering have been fabricated via foaming [84, 85], porogen-solvent techniques, cryogelation [86], photodegradation [87, 88], and self-assembly of microspheres [89]. While these techniques are able to recapitulate alveolar-like structures, they lack the vasculature and airways required for integration into recipients and ultimately for gas exchange. However, a recent report showed that a 3D gelatin microbubble scaffolds seeded with murine pluripotent stem cells promoted angiogenesis when implanted [84]. Thus if these constructs could somehow be hooked up to an air supply and the boundaries of the blood-air barrier were thin enough, it is conceivable that these constructs could support gas exchange. Whilst important as proof of concept studies, none of these subtractive or bulk manufacturing techniques have been successful in generating functional lung tissue and incorporation of vasculature has not yet been explored. Synthetic materials could be of immense value for generating lung scaffolds due to the ability to precisely and reproducibly manufacture them for individual patients, but suitable manufacturing

methods are not yet known. However, there are approaches which have been used in other organs which may be worthwhile exploring for lung tissue which will be discussed below.

Potential Manufacturing Methods to Generate Porous Scaffolds for Lung Tissue Engineering

From a simplistic viewpoint, the lung parenchyma is a system of interconnected porous-like structures surrounded by a capillary bed to facilitate gas exchange [83]. There are several different manufacturing methods which have been used for tissue engineering porous structures for other organs such as freeze drying, foaming, solvent-casting and particulate-leaching techniques [90]. Manufacturing processes have also been developed for generating perfusable vascular channels in tissue engineered constructs [91].

Electrospinning is an additive manufacturing technique which has emerged as an effective method of producing nanoscale fibres for use in multiple fields, including tissue engineering of blood vessels [92], skin [93] and trachea [75]. Both synthetic and natural polymers can be used for electrospinning to create porous scaffolds comprised of thin nanofibers which have been shown to be capable of supporting cell attachment, proliferation and differentiation. By controlling fibre parameters such as size, density, composition and orientation, fibrous structures which are similar to the ECM can be produced. Moreover, molecules such as growth factors or pharmaceuticals can be included in the scaffold to influence and direct regeneration of the tissue spatially or temporally. Electrospinning has already been used as an *in vitro* platform for studying the effects of fibrotic lung micro-environments on various cell types [22]. Overall, electrospinning is a promising technique, yet has been only limited to creating an *in vitro* assay platform and has not yet been used for bioengineering lung tissue.

Techniques which are amenable to creating custom-made, reproducible, intricate 3D designs using cytocompatible materials would be ideal for tissue engineering. 3D printing, or bioprinting when cells are printed, has recently emerged as a potential source for bioengineering tissues or supporting structures [94-100]. 3D printing has been applied clinically for treatment of tracheobronchomalacia

(TBM) [101] and tracheal collapse with 3D printed patient-specific tracheal splints [102]. However, in these instances, the 3D printing technology was simply used for supporting structures and not for regenerating transplantable tissue in humans. 3D printing has been explored for tissue engineering of organs such as rat trachea using a scaffold-free approach [103] skin [104], cartilage [105], aortic valve conduits [106], and vascular tissue [107] but there are currently no published reports of attempts to 3D print lung tissue capable of gas exchange. 3D bioprinting of distal lung will be extremely challenging, as the gas exchange barrier is on the order of nanometres and nozzles used for printing cells need to be in the micrometre range. Thus, new 3D printing or manufacturing approaches need to be developed to overcome this limitation. On the other hand, 3D printing technologies are advanced enough for printing structures at the resolution of trachea and bronchus, but materials and manufacturing methods compatible with cells have not yet been reported.

One challenge in 3D printing of biologic tissue is that many current techniques for printing high resolution structures use processes that are incompatible with directly printing cells and many biologic materials. Traditional 3D printing approaches rely on solvents or heating to generate polymer solutions which can flow as liquids through the 3D printing nozzles. Thus, these limitations have contributed to slow progress in 3D printing of lung and other tissues.

It is important that the material printed does not degrade before new ECM is synthesized, deposited and organised by seeded cells which can support the structure of the tissue and handle any mechanical loading (*e.g.* further cell seeding, bioreactor parameters and surgical handling) [108]. Thus, the degradation kinetics and the impact of the degradation products are important parameters to consider when selecting, designing and validating potential new biomaterials for pulmonary tissue engineering applications. These and other issues need to be addressed for successful application of manufactured scaffolds for generating lung or airway tissue.

Hybrid Materials

While both acellular scaffolds and manufactured scaffolds have shown progress, ultimately, neither may be the optimal scaffold material alone. In many other manufacturing fields, optimal materials are derived through the use of hybrid or composite materials whereby the positive attributes of two or more materials can be combined to generate a final material with optimal overall properties which overcome the limitations of the individual components it is comprised of. Using hybrid or composite materials to manufacture scaffolds might therefore be an ideal solution as the biologically conducive nature of the ECM-derived scaffold material, such as sites for cell adhesion and organisational and differentiation cues, could be combined with synthetic materials and advanced manufacturing approaches to produce more reproducible products with tunable or controllable mechanical properties.

Cell types and scaling-up cell culture methods

In addition to identifying methods to reproducibly manufacturing suitable scaffolds for lung tissue engineering using either acellular or manufactured scaffolds, an additional challenge is in identifying cell sources and obtaining sufficient cell numbers. Ideally, autologous cells from the patient would be used for recellularising lung scaffolds in order to minimise post-transplantation immune complications and the need for immunosuppressive medications. However, ideal GMP grade manufacturing methods for mass production of the different cells likely needed for lung bioengineering are currently not widely established.

Fully differentiated primary adult cells and/or autologous endogenous lung progenitor cells could be a potential source. Yet, when using such an approach, multiple cell types would likely need to be isolated from the patient, grown to sufficient numbers *ex vivo*, and introduced into the scaffold in the correct locations in order to generate functional lung tissue.

While our understanding of what a 'fully differentiated' or adult cell type is in the lung is constantly evolving, the use of terminally differentiated cell types would not allow for repair of the lung following injury. Therefore, endogenous progenitor cells, known to participate in adult repair processes, may be a more reasonable approach. One potential approach for regenerating the multiple cell types in the lung could be to seed multiple progenitor cell populations into the lung scaffold with the ultimate goal of directing differentiation into the different cell types found in the adult lung. This would avoid the necessity of having to introduce each different cell type into the lung and direct it to its correct anatomical location. Two exciting recent reports demonstrated that sufficient numbers of endogenous epithelial progenitor cells could be sourced from a single patient and expanded *ex vivo* to cover either tracheal grafts or a large extent of whole acellular human lung lobes [66, 109]. It is critical that these expansion methods are reliant on substances that are permissible for clinical use in humans [109]. Further development is needed to generate scalable methods using GMP grade manufacturing approaches to ensure sufficient epithelial, endothelial, or mesenchymal cell coverage. An additional limitation may also lie in identifying suitable endogenous progenitor cell populations from patients with existing lung disease. This may be challenging as there is emerging evidence that these cells are aberrant in chronic lung diseases [110-112]. However, this will be an interesting line of future research as previous reports indicate that the scaffold source influences cell behaviour more strongly than cell origin [26]. Thus, a normal scaffold may help revert the phenotype of cells obtained from diseased patients.

An alternative approach to endogenous progenitor cells is iPS cells. These are of particular interest as recent work has demonstrated that human iPS cells can be differentiated into cells expressing a distal pulmonary epithelial cell phenotype and seeded into acellular human lung scaffolds [61, 63]. Moreover, in patients with lung disease caused by known gene alterations, such as cystic fibrosis, iPS cells derived from these patients could be gene-corrected prior to subsequent recellularisation [65, 113]. Yet, iPS cells also have several potential disadvantages: currently a patient

skin biopsy is typically used to make iPS cells, but it has been shown that these cells partially retain the epigenetic memory of their tissue of origin [114]. This, whilst not yet explored in detail, could lead to limitations when differentiating iPS cells into specific lung lineages. Nonetheless, several studies have shown that iPS cells derived from fibroblasts can be used to derive cells containing phenotypic and functional markers of mature lung epithelial cell types [63-65, 115, 116]. Other studies have also examined the use of embryonic stem cells (ESC) and found that these can be differentiated towards different adult epithelial phenotypes *ex vivo* [62, 68]. Despite their promise, ESC cells carry ethical concerns and both ESCs and iPSCs have been shown to form teratomas [117, 118]. Thus both ESC and iPSCs need to be further optimised and thoroughly investigated prior to clinical use.

Recent reports show promise for large scale production and culture of cells using suspension culture (stirring) bioreactors and rotating wall bioreactors [63, 119], including techniques compliant with GMP and thus clinical use [36, 119-121]. This could allow for translation of stem cell research to clinical and pre-clinical applications modelling a potential GMP workflow. However, large scale production of cells will need to be optimised for each cell type. Despite these advances, it is evident that new methods that decrease cost and time will be needed for a cost-effective and less labour-intensive large-scale production of cells for clinical use.

Table 1a: Compiled studies of breakthrough advances within the field of *ex vivo* lung tissue engineering

	Year	Material	Method	Scaffold	Significant Advance	Endpoints	Reference
Synthetic	2006	Polyglycolic acid and pluronic F-127 hydrogel	Microfabrication techniques	Alveoli-like structures	Growth of lung progenitor cells on a synthetic scaffold and transplanted	<i>in vitro, in vivo</i>	[122]
	2006	Poly-DL-lactic acid (PDLLA)	Microfilm templates and 3D foam	Alveoli-like structures	Alveolar epithelial cells can be grown on porous synthetic materials	<i>in vitro</i>	[123]
	2012	Decorin containing matrices	Electrospinning	Trachea	Electrospinning decorin matrices for a tissue-engineered trachea	<i>in vitro</i>	[75]
	2013	Hydroxyethyl methacrylate-alginate-gelatin cryogel	Cryogelation	Alveoli-like structures	Macroporous matrix with ability to recruit cells when implanted <i>in vivo</i>	<i>in vitro, in vivo</i>	[86]
	2014	Gelatin/microbubble scaffold	Microfluidics	Alveoli-like structures	Differentiation of lung stem/progenitor cells into alveolar pneumocytes and induction of angiogenesis within a manufactured scaffold	<i>in vitro, in vivo</i>	[84]
	2015	Poly(ethylene glycol) (PEG)-based hydrogel	Microsphere templates	Alveoli-like structures	Cytocompatible manufacturing method for co-culture of alveoli-like structures	<i>in vitro</i>	[88]
	2016	POSS-PCU	Dispersion of porogens	Trachea	Use of engineered pores to improve integration capacity of a synthetic scaffold	<i>in vitro, in vivo</i>	[74]
	2017	Alginate beads	Alginate beads	Alveoli-like structures	Self-assembled alveoli-like structures with human cells	<i>in vitro</i>	[89]
	2018	MMP degradable Poly(ethylene glycol) (PEG)-based hydrogel	Microsphere templates	Alveoli-like structures	Controlled degradation with specific MMP cleavable sites in alveolar like structures	<i>in vitro</i>	[87]
Acellular	1981	Alveolar basement membrane (various origin)	Decellularisation	Alveolar basement membrane	First decellularisation attempt to obtain alveolar basement membrane	<i>in vitro</i>	[124]
	1986	Human alveolar an amniotic matrix	Decellularisation	Acellular alveolar vs. amniotic basement membranes	First repopulation experiment on acellular lung tissue; differentiation on various basement membranes	<i>in vitro</i>	[125]
	2010	Rat lung	Decellularisation	Rat acellular lung	Orthotopic transplantation	<i>in vitro, in vivo</i>	[70]

2010	Rat lung	Decellularisation	Rat acellular lung	Orthotopic transplantation and first report of decellularisation of human lung	<i>in vitro, in vivo</i>	[126]
2011	Rat lung and liver	Decellularisation	Rat acellular lung and liver	Cellular differentiation on the scaffolds	<i>in vitro</i>	[127]
2012	Mouse lung	Decellularisation	Mouse acellular lung and slices	Comparison of different detergent-based protocols for mouse lung de- and recellularisation	<i>in vitro</i>	[54]
2012	Human lung	Decellularisation	Human acellular lung and slices	De- and recellularisation of human normal and fibrotic lungs	<i>in vitro</i>	[51]
2013	Human and porcine lung	Decellularisation	Human and porcine lung and slices	De- and recellularisation of human and porcine lungs	<i>in vitro</i>	[34]
2013	Mouse lung	Decellularisation	Mouse acellular lung and slices	Effects of age and emphysematous and fibrotic injury on murine recellularisation	<i>in vitro</i>	[128]
2013	Mouse lung	Decellularisation	Mouse acellular lung and slices	Effects of storage and sterilization on de- and recellularised whole lung	<i>in vitro</i>	[44]
2014	Human and porcine lung	Decellularisation	3D lung segments	Small segments to retain 3D lung structure in acellular scaffolds from large animals and human origin for physiologic recellularisation	<i>in vitro</i>	[24]
2014	Rat and human lung	Decellularisation	Rat and human acellular lung	Transplant of iPS-derived re-epithelialised and re-endothelialised scaffold	<i>in vitro, in vivo</i>	[53]
2015	Rat and human lung	Decellularisation	Rat and human acellular lung	Regeneration of functional pulmonary vasculature	<i>in vitro, in vivo</i>	[67]
2016	Porcine lung	Decellularisation	Porcine lung ECM hydrogel	First ECM hydrogel derived from acellular lung	<i>in vitro, in vivo</i>	[129]
2016	Porcine lung: WT, alpha-gal KO	Decellularisation	Porcine lung	Comparison of de- and recellularisation of WT and α 1,3 Galactosyltransferase knockout pig lungs, identification of residual immunogens in WT lungs	<i>in vitro</i>	[25]
2017	Porcine lung	Decellularisation	Porcine lung	Orthotopic transplantation of porcine scaffold recellularised with human cells	<i>in vitro, in vivo</i>	[36]
2006	Poly-lactic-co-glycolic acid (PLGA), poly-L-lactic-acid (PLLA), and Matrigel porous foam and nanofibrous matrix	Microfabrication techniques	Alveoli-like structures	First hybrid material attempt for lung tissue engineering	<i>in vitro</i>	[82]
2008	Matrigel plug combined with FGF2	Microfabrication techniques	Vascularised pulmonary tissue	Distal pulmonary epithelial differentiation can be maintained <i>in vivo</i> ,	<i>in vitro, in vivo</i>	[130]

		loaded polyvinyl sponge		constructs	donor-derived ECs contribute to the formation of vessels		
	2011	Lung extract-coated PCL nanofibers	Electrospinning	Electrospun nanofibers coated with lung extracts from fibrotic or non-fibrotic mice	<i>Ex vivo</i> system to recapitulate the 3D fibrotic lung microenvironment	<i>in vitro</i>	[22]
	2011	Collagen–Matrigel/alginate microcapsules	Microsphere encapsulation	Alveoli-like structures	Fibroblasts, epithelial cells and alveolar type II form alveolus-like structures in collagen–Matrigel/APA microcapsules engineered scaffolds	<i>in vitro</i>	[131]
	2017	PCL/decellularised aorta	Electrospinning, Decellularisation	Electrospun PCL stents in acellular rabbit aorta	Hybrid trachea scaffold for tracheal replacement	<i>in vitro, in vivo</i>	[132]
Cells	2014	Human pluripotent stem cells	NA	NA	Functional hPSC-derived distal lung epithelial cells seeded onto human scaffold	<i>in vitro, in vivo</i>	[61]
	2015	Human endothelial and perivascular cells	NA	NA	Regeneration of functional pulmonary vasculature	<i>in vitro, in vivo</i>	[67]
	2016	Human respiratory epithelial cells	NA	NA	Scalable cell culture system	<i>in vitro, in vivo</i>	[109]
	2016	KRT5+TP63+ basal epithelial stem cells	NA	NA	Recellularisation	<i>in vitro</i>	[66]
	2018	Chondrocytes, endothelial cells, MSCs	3D Bioprinting	None	Scaffold-free manufacturing of a rat trachea mimic	<i>in vitro, in vivo</i>	[103]

Table 1b: Challenges within the field of *ex vivo* lung tissue engineering

Area	Focus for future research/Future perspectives
Scaffold source	Can a suitable acellular xenograft source be identified? Can allogeneic human scaffolds be used? Does the age (neonatal or aged) of the scaffold impact the biomaterial? Evaluate immunogenicity of scaffold with and without cells
Cell sources	Are all 40 cell types found within the lung required to make a functional lung? Can allogeneic cells be used or do we need to use autologous cells? Where will we source cells for patients with chronic or genetic lung diseases? What types of cell sources can be used (<i>e.g.</i> endogenous progenitor cells, iPS cells)
Manufacturing	Which GMP manufacturing method will be suitable for scaffold generation, storage and maturation? Which standardised approaches for the characterisation and validation of the scaffold will be required? How can we obtain enough cells to recellularise and how will they be re-introduced into the scaffold? Will bioengineered lungs need to be tailored for patients with specific lung diseases (<i>e.g.</i> the main lung transplant recipients (COPD, CF, IPF, PAH))?
Maturation	Will different bioreactors be needed for the different cell types in the lung? What time span and/or maturation level will be required? What degree of vascularisation of the scaffold will be required?
Surgical and clinical approach	How will we assess the functionality prior to transplantation? Will EVLP parameters be enough to predict success? What surgical techniques could be used for pieces of bioengineered lung tissue? Will special postoperative care be required? Will the patients need to be immunosuppressed?

Bioreactor strategies for lung bioengineering

While the study of perfusion and ventilation is more straightforward in studies using acellular, intact lungs, there are still relatively few studies which have addressed these parameters [133-135], in large part due to the limited availability of suitable lung bioreactors. Various bioreactor strategies have been developed in the last years for lung and airway bioengineering approaches or reconditioning of the lungs that were rejected for transplantation [7, 136]. Ghaedi et al developed a rotating bioreactor which exposed cells seeded onto thin slices of acellular lung to air and liquid alternately which resulted in alveolar epithelial cell expansion [137]. For de- and recellularisation of human sized lungs, Gilpin et al developed a pressure-controlled apparatus where cell seeding was performed via gravitational force [52]. A commercially available isolated lung perfusion system called the Organ Regenerative Control Acquisition bioreactor (Harvard Apparatus Regenerative Technologies) has also been used by others for decellularisation [34, 35, 138]. Despite the advances made in the last few years with EVLP systems, the maximal amount of time that a healthy lung can be maintained *ex vivo* and transplanted is in the range of 6 hours [139-141]. It is thought that bioengineering lungs *ex vivo* will require a far longer period of maturation time in a bioreactor prior to transplantation. An emerging approach for bioengineering of the upper airways, where mostly horizontal or upright bioreactors have been utilized before [142], is using the human body as a bioreactor. For instance, Delaere et al bioengineered an allogeneic donor trachea first at the forearm of the recipient and then replaced the damaged trachea with the allograft [143, 144]. Attempts for *de novo* generation of organs also include the use of humanised animals such as pigs as bioreactors [145, 146]. Interestingly, a recent report using native porcine lungs in a cross-circulation model reported an *ex vivo* period of 36 hours, but transplantation was not evaluated as an outcome [5]. Regardless of the *ex vivo* approach, ensuring that the developing lung or airway tissue receives sufficient nutrients and is developing properly will be important to examine in more detail in future studies (see **Table 1b**). Incorporation of real-time measurements in addition to vascular

resistance such as glucose, lactate, electrolytes, pH and mechanical ventilation properties will be important to understand the necessary *ex vivo* culture time and help to design smarter bioreactor strategies.

Regulatory and ethical implications for translating lung bioengineering approaches

Despite the recent and exciting advances made in lung bioengineering, a number of significant regulatory, ethical and practical challenges will need to be addressed for any of these technologies to enter the clinic on a larger scale. Each set of challenges (*e.g.* classification of regenerative medicine products, approval of materials, use of stem cells, *etc.*) will be unique to the bioengineering approach used. When developing these new potential therapeutic approaches, it is critical that these translational concerns are addressed as early in the product development pipeline as possible. Establishment of regulatory frameworks and GMP standards for tissue engineered products and the enforcement of these is necessary to prioritise patient safety [147, 148]. Additionally, it remains completely unknown as to what the evaluation criteria should be used for bioengineered lung tissue before the first in man clinical trials would be performed, but the use of parameters comparable to those used in EVLP may be a good first indication [149]. Moreover, the use of an appropriate large animal model which examines both short and long term outcomes will be necessary before these approaches are translated to the clinic. It will be critical for academic researchers, clinicians, industry and regulatory bodies to work with one another to establish these new frameworks.

To date, the majority of studies which have used human lungs for decellularisation are lungs which do not meet the clinical criteria for transplantation or alternatively are lungs from normal patients undergoing autopsy for a non-lung related death. Human tissue access for biomedical research differs significantly between different countries [150-152]. Therefore, if de- and recellularisation is to be realized on a larger scale and in the clinic, regulatory frameworks will need to be permissible for these

technologies in each country. One potential unexplored source for generating acellular human lung scaffolds could be from DCD donors. DCD donors are used in many countries, but not all countries permit their usage due to ethical concerns. In most countries, DCD lungs are evaluated using EVLP prior to transplantation. However, a large portion of DCD donors are not used for transplant since they fail to obtain the minimal criteria necessary for transplantation (primarily low blood gas values) after being evaluated *ex vivo* [153]. If all of these sources of human lung tissue can be used and bioengineering strategies can be designed to reproducibly generate functional lung tissue for transplantation, the biggest limiting factor will likely become the cost of manufacturing bioengineered lungs for all of the patients on waiting lists.

While synthetic materials are not limited by these same ethical and regulatory restrictions with regarding to identifying a suitable source, a major hurdle for the use of synthetic materials is the time and overall cost required for a material to receive EMA or FDA approval, which includes thorough characterisation of *in vitro* and *in vivo* material properties [154, 155]. Moreover, the regulation of stem cell and regenerative medicine products is a rapidly evolving area which varies greatly by country. In the last few years, countries, such as Japan [156], have adopted new regulatory pathways which differ dramatically from the traditional paths to translation which have long-existed in most countries [152]. Therefore, the ability to conduct pre-clinical trials and ultimately the path to the clinic will be different in each country.

Discussion and Outlook

While significant progress has been made in bioengineering lung or airway tissue *ex vivo* with the ultimate goal of transplantation (see **Table 1a** for a summary of significant advances), most of the proof of concept studies for lung bioengineering have focused on endothelial and epithelial compartments. In order to generate functional lung tissue which will be able to function long term, the

over 40 different cell types and perhaps hundreds to thousands of different cellular subtypes will likely need to be recapitulated. However, it is currently not clear which of these cell types are essential to produce lung tissue which can minimally function *in vivo*. In one recent and innovative approach, the issue is raised as to whether all cells should be removed during decellularisation. Dorrello et al. developed techniques to selectively decellularise the epithelium, but retain the endothelium [157]. Such a technique could be employed either *ex vivo* or *in vivo*. It is known that an intact vascular network is critical for transplantation as well as for maintaining the blood-gas barrier and allowing for proper graft function, but also for supporting the regenerative cells [158]. Removing only epithelial cells and retaining the vascular endothelium might be an option to increase the success of re-seeding and implantation for certain patients. However, in chronic lung disease patients where the vasculature is severely damaged (e.g. PAH), this may not be a suitable approach.

One major intriguing question in the use of acellular lung scaffolds is the challenge of recellularising the interstitial spaces and the importance of innervation of smooth muscle cells. Will the cells seeded into decellularised constructs extravasate through the existing basement membranes? Will reseeded fibroblasts or smooth muscle cells simply 'find their way' to the appropriate anatomical location if seeded through the airways or the vasculature? How critical is innervation and how will this be achieved within the scaffold and integrated into the recipient nervous system? While manufacturing techniques such as 3D printing might help overcome some of the challenges with regard to spatially depositing cells, there are other challenges such as incorporating and controlling multiple nozzles with each cell type and generating structures at length scales capable of gas exchange.

It will be important to more fully understand the behaviour of seeded cells into acellular, synthetic or hybrid scaffolds, and any subsequent remodelling of the ECM or immune response. It is currently unclear how "clean" a scaffold needs to be for lung tissue engineering approaches. Evidence from pre-clinical studies [159] and clinical use of other acellular scaffolds indicates that the processing of

acellular scaffolds can influence their immunogenicity [48, 160]. In general, immune cells have not been introduced into any *ex vivo* bioengineering schemes; therefore, immunogenic responses would be limited to those which are a result of the recipient's immune system. Immune cells have been found to be able to induce pathologic responses in fibroblasts seeded on acellular lung scaffolds, indicating their potential role in directing cell fate of cells seeded on acellular scaffolds [161]. Interestingly, immune cells, such as macrophages, have recently been found to play a prominent role in directing normal alveolar regeneration *in vivo* [162]. Thus, the role of different immune cell populations in directing *ex vivo* regeneration and their potential role in regulating *in vivo* regeneration will be an interesting area of future investigation. Some tolerable amount of immunogenic proteins might help facilitate regeneration and maturation into functional tissue for transplantation during the *ex vivo* phase of maturation. Lung transplant recipients are currently placed on broad spectrum immunosuppressive agents because a wide range of different immune cell populations (neutrophils, B cells, T cells, macrophages, *etc.*) have been implicated in lung transplant rejection – both acute and chronic rejection [31]. Whether or not this will be needed to the same extent for transplantation of a bioengineered lung is not yet known.

In addition, it is critical that future studies in the field more fully characterize and understand the potential functionality of bioengineered lung tissue (see **Table 1b**). In clinical lung transplantation, patient demographics such as age, smoking history, absence of chest trauma, and absence of malignancy are important criteria for selecting suitable donors while functional criteria for donor lungs is ABO compatibility, clear chest radiograph, $\text{PaO}_2 > 300$ on $\text{FiO}_2 = 1.0$, and PEEP 5 cm H_2O [163]. For lungs reconditioned with EVLP, the current functional criteria differs between centers (eg. Toronto, Lund or OCS protocol) [164]. Thus, one could envision that the minimal functional criteria for a bioengineered lung would be $\text{PaO}_2 > 350\text{-}400$ on $\text{FiO}_2 = 1.0$, and PEEP 5 cm H_2O , which is what is used for EVLP assessment [165]. Other standardized approaches for evaluation could be: blood gases from each

bioengineered lobe, bronchoscopy, LDH values, ROS production, bronchio-alveolar lavage (BAL) analysis (of protein and inflammatory cytokines), and surfactant evaluations.

While patent vasculature and gas exchange may be the most critical initial functions for evaluating whether a transplant could proceed and have thus been the focus of previous studies [67], a bioengineered lung tissue and the cells within should ideally also be able to respond to the environment—meaning that other functions are likely necessary for longer term functionality. Among these on the epithelial side are ciliary beating and clearance of inhaled particles and allergens, mucociliary clearance and surfactant production. On the endothelial side, the ability of constructs to support events such as haemostasis and leukocyte extravasation in the context of lung injury will be important to explore in future studies. More broadly, any tissue engineered construct should have the ability to respond appropriately to potential challenges and injuries and repair locally. Thus, how the recipient immune system may repopulate transplanted lung tissue remains almost entirely unexplored and may be incredibly important, especially given emerging evidence that the lung harbours haematopoietic progenitor cells and is a major site of platelet biogenesis in the body (up to 50% of total platelet production) [166]. Further, it remains incompletely understood how recruited, monocyte-derived macrophages differ from tissue-resident macrophages in the lung [167], but they have been shown to be important for regeneration of the distal lung [162]. Whether or not these and other immune cells will need to be present or intentionally seeded in an *ex vivo* regeneration scheme remains unknown.

Currently, there are five major types of patients who receive the majority of lung transplants (COPD, IPF, PAH, CF, and Alpha 1 Antitrypsin Deficiency (A1AD)). In all chronic lung diseases (eg. COPD, IPF, and PAH), there are known defects in the endogenous lung progenitor cell populations. Thus in the absence of gene correction or modulation with exogenous factors, it is unclear if these cell types can be

used in a lung bioengineering scheme. iPS cells might therefore be considered the most promising source of cells for a clinically relevant scheme. However, in both CF [65, 168] and PAH [169], mutations are also found in iPS derived lung epithelial progenitor and endothelial cells, respectively. Recent techniques have shown that iPS derived lung epithelial progenitor cells from CF patients can be gene corrected *ex vivo* [65]. Due to the differences in potential cell sources for patients with specific lung diseases, it is clear that the bioengineering approach will not be a one size fits all solution and will need to be modified for each of the different major groups of lung transplant patients and perhaps for each patient if individual mutations need to be gene corrected.

In addition to approaches which aim to generate single or double lungs, there could be clinical impact in reconstructing single lobes or only pieces of lung tissue. While single or double lung transplant is standard, transplantation of single lobes is only performed in some centres, but could be beneficial for certain patient groups, such as COPD and A1AD patients [170]. Furthermore, single lobe transplant from an adult donor has been performed in paediatric patients where size matching is challenging with adult donors [171]. Thus, bioengineered single lobes could be of use. Clinical conditions where only a portion of the parenchyma or airway is affected (*e.g.* trauma, local bronchiectasis, tracheal collapse, non-small cell lung cancer) could benefit from these approaches. Techniques to manufacture alveolar-like structures [84, 87, 88, 131], tracheal supports [101, 102] and replacements [148] have all been recently developed. Furthermore, there has been work on development of biomaterials which can serve as artificial pleuras for diseases and acute conditions which affect the visceral pleura (*e.g.* pneumothorax, mesothelioma) [172, 173]. Thus, there may be potential clinical impact for partial reconstruction or replacement of lung tissue with tissue engineered products in patients where only certain regions of the lung are damaged.

The pursuit of lung bioengineering approaches for regenerating lung tissue for transplantation has opened new opportunities for *ex vivo* modelling of different lung diseases. While there has been less research on the use of synthetic materials in modelling lung disease, this is an emerging area of research with large potential to help model new aspects of lung disease which current models cannot address. Acellular lungs derived from patients with chronic lung disease more completely recapitulate the clinical heterogeneity and more faithfully mimic the clinical disease. In the pursuit of bioengineering lung tissue for transplantation, the approaches developed can also be used for performing drug screens, replacement of animal models, and better understanding of different lung diseases and regeneration. However, the majority of studies have been done under simplified conditions which do not completely recapitulate the *in vivo* scenario. Future incorporation of immune cells as well as physiological parameters such as ventilation, perfusion, and control of oxygen levels should be examined.

Tissue engineering of (complex) organs was once thought to be restricted to the realm of science fiction. However, the exciting recent advances made in the tissue engineering field are supportive of the idea that these technologies may indeed one day lead to therapies for patients with devastating and debilitating lung diseases. The recent significant advances made in lung tissue engineering have been made largely due to the collaboration between biologists, chemists, material scientists, clinicians and engineers in both academia and industry; the realization of lung tissue and airway engineering technologies in the clinic will be contingent on the continued evolution and successful integration of these fields.

Acknowledgments

The authors thank all the members of the Lung Bioengineering and Regeneration Lab for helpful discussions throughout the manuscript preparation and for critical reading of the final manuscript. This work was funded by Wallenberg Molecular Medicine Fellowships (DEW and SL) from the Knut and Alice

Wallenberg Foundation and a Helmholtz Munich Postdoctoral Fellowship (DEW). The authors are grateful to Dr. Ewald Weibel (University of Berne, Switzerland) for the insightful discussions and electron microscopy images and Dr. Scott Randell (University of North Carolina, School of Medicine, US) for histological images. We also thank Alice Caiado (London College of Communication, University of Arts London, UK) for providing some of the lung graphics within the manuscript.

References

1. European Respiratory Society. The economic burden of lung disease. ERS White Book 2017 [Available from: <http://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/>].
2. European Commission. Journalist workshop on organ donation and transplantation. Recent Facts & Figures 2014 [Available from: http://ec.europa.eu/health/sites/health/files/blood_tissues_organ/docs/ev_20141126_factsfigures_en.pdf].
3. Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report 2015; Focus Theme: Early Graft Failure. *The Journal of Heart and Lung Transplantation*. 2015;34(10):1264-77.
4. Fisher A, Andreasson A, Chrysos A, Lally J, Mamasoula C, Exley C, et al. An observational study of Donor Ex Vivo Lung Perfusion in UK lung transplantation: DEVELOP-UK. *Health technology assessment (Winchester, England)*. 2016;20(85):1-276.
5. O'Neill JD, Guenthart BA, Kim J, Chicotka S, Queen D, Fung K, et al. Cross-circulation for extracorporeal support and recovery of the lung. *Nature Biomedical Engineering*. 2017;1:0037.
6. Cypel M, Yeung JC, Liu M, Anraku M, Chen F, Karolak W, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. *The New England journal of medicine*. 2011;364(15):1431-40.
7. Ingemansson R, Eyjolfsson A, Mared L, Pierre L, Algotsson L, Ekmeahag B, et al. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. *The Annals of thoracic surgery*. 2009;87(1):255-60.
8. Machuca TN, Mercier O, Collaud S, Tikkanen J, Krueger T, Yeung JC, et al. Lung transplantation with donation after circulatory determination of death donors and the impact of ex vivo lung perfusion. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2015;15(4):993-1002.
9. Shaver CM, Diamond JM, Schrepfer S, Cantu E. Optimization of oxygenation during ex vivo lung perfusion-Best basic science article in 2017. *The Journal of Heart and Lung Transplantation*. 2018.
10. Franks TJ, Colby TV, Travis WD, Tudor RM, Reynolds HY, Brody AR, et al. Resident cellular components of the human lung: current knowledge and goals for research on cell phenotyping and function. *Proceedings of the American Thoracic Society*. 2008;5(7):763-6.
11. Burgstaller G, Oehrle B, Gerckens M, White ES. The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease. *European Respiratory Journal*. 2017;50(1).
12. Langer R, Vacanti JP. Tissue engineering. *Science (New York, NY)*. 1993;260(5110):920-6.
13. Atala A, Bauer SB, Soker S, Yoo JJ, Retik AB. Tissue-engineered autologous bladders for patients needing cystoplasty. *Lancet (London, England)*. 2006;367(9518):1241-6.
14. Shin'oka T, Matsumura G, Hibino N, Naito Y, Watanabe M, Konuma T, et al. Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. *The Journal of thoracic and cardiovascular surgery*. 2005;129(6):1330-8.
15. Wagner DE, Bonvillain RW, Jensen T, Girard ED, Bunnell BA, Finck CM, et al. Can stem cells be used to generate new lungs? Ex vivo lung bioengineering with decellularized whole lung scaffolds. *Respirology (Carlton, Vic)*. 2013;18(6):895-911.
16. Gilpin SE, Charest JM, Ren X, Ott HC. Bioengineering Lungs for Transplantation. *Thoracic surgery clinics*. 2016;26(2):163-71.
17. Calle EA, Leiby KL, Raredon MB, Niklason LE. Lung regeneration: steps toward clinical implementation and use. *Current opinion in anaesthesiology*. 2017;30(1):23-9.
18. Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. *Biomaterials*. 2011;32(12):3233-43.
19. Badylak SF, Taylor D, Uygun K. Whole-organ tissue engineering: decellularization and recellularization of three-dimensional matrix scaffolds. *Annual review of biomedical engineering*. 2011;13:27-53.
20. Freytes DO, Martin J, Velankar SS, Lee AS, Badylak SF. Preparation and rheological characterization of a gel form of the porcine urinary bladder matrix. *Biomaterials*. 2008;29(11):1630-7.

21. Wagner DE, Bonenfant NR, Parsons CS, Sokocevic D, Brooks EM, Borg ZD, et al. Comparative decellularization and recellularization of normal versus emphysematous human lungs. *Biomaterials*. 2014;35(10):3281-97.
22. Fischer SN, Johnson JK, Baran CP, Newland CA, Marsh CB, Lannutti JJ. Organ-derived coatings on electrospun nanofibers as ex vivo microenvironments. *Biomaterials*. 2011;32(2):538-46.
23. O'Neill JD, Anfang R, Anandappa A, Costa J, Javidfar J, Wobma HM, et al. Decellularization of human and porcine lung tissues for pulmonary tissue engineering. *Ann Thorac Surg*. 2013;96(3):1046-55; discussion 55-6.
24. Wagner DE, Bonenfant NR, Sokocevic D, DeSarno MJ, Borg ZD, Parsons CS, et al. Three-dimensional scaffolds of acellular human and porcine lungs for high throughput studies of lung disease and regeneration. *Biomaterials*. 2014;35(9):2664-79.
25. Platz J, Bonenfant NR, Uhl FE, Coffey AL, McKnight T, Parsons C, et al. Comparative Decellularization and Recellularization of Wild-Type and Alpha 1,3 Galactosyltransferase Knockout Pig Lungs: A Model for Ex Vivo Xenogeneic Lung Bioengineering and Transplantation. *Tissue engineering Part C, Methods*. 2016;22(8):725-39.
26. Parker MW, Rossi D, Peterson M, Smith K, Sikstrom K, White ES, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. *The Journal of clinical investigation*. 2014;124(4):1622-35.
27. Parker MW, Rossi D, Peterson M, Smith K, Sikström K, White ES, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. *The Journal of clinical investigation*. 2014;124(4):1622-35.
28. Godin LM, Sandri BJ, Wagner DE, Meyer CM, Price AP, Akinola I, et al. Decreased Laminin Expression by Human Lung Epithelial Cells and Fibroblasts Cultured in Acellular Lung Scaffolds from Aged Mice. *PLoS one*. 2016;11(3):e0150966.
29. Gilpin SE, Li Q, Evangelista-Leite D, Ren X, Reinhardt DP, Frey BL, et al. Fibrillin-2 and Tenascin-C bridge the age gap in lung epithelial regeneration. *Biomaterials*. 2017;140:212-9.
30. Arenas-Herrera JE, Ko IK, Atala A, Yoo JJ. Decellularization for whole organ bioengineering. *Biomedical materials (Bristol, England)*. 2013;8(1):014106.
31. Shaver CM, Ware LB. Primary graft dysfunction: pathophysiology to guide new preventive therapies. *Expert review of respiratory medicine*. 2017;11(2):119-28.
32. Mizota T, Miyao M, Yamada T, Sato M, Aoyama A, Chen F, et al. Graft dysfunction immediately after reperfusion predicts short-term outcomes in living-donor lobar lung transplantation but not in cadaveric lung transplantation. *Interactive cardiovascular and thoracic surgery*. 2016;22(3):314-20.
33. Bonvillain RW, Danchuk S, Sullivan DE, Betancourt AM, Semon JA, Eagle ME, et al. A Nonhuman Primate Model of Lung Regeneration: Detergent-Mediated Decellularization and Initial In Vitro Recellularization with Mesenchymal Stem Cells. *Tissue Engineering Part A*. 2012;18(23-24):2437-52.
34. Nichols JE, Niles J, Riddle M, Vargas G, Schilagard T, Ma L, et al. Production and assessment of decellularized pig and human lung scaffolds. *Tissue engineering Part A*. 2013;19(17-18):2045-62.
35. Price AP, Godin LM, Domek A, Cotter T, D'Cunha J, Taylor DA, et al. Automated decellularization of intact, human-sized lungs for tissue engineering. *Tissue Eng Part C Methods*. 2015;21(1):94-103.
36. Zhou H, Kitano K, Ren X, Rajab TK, Wu M, Gilpin SE, et al. Bioengineering Human Lung Grafts on Porcine Matrix. *Annals of surgery*. 2017.
37. Balestrini JL, Gard AL, Gerhold KA, Wilcox EC, Liu A, Schwan J, et al. Comparative biology of decellularized lung matrix: Implications of species mismatch in regenerative medicine. *Biomaterials*. 2016;102:220-30.
38. Barnard JB, Davies O, Curry P, Catarino P, Dunning J, Jenkins D, et al. Size matching in lung transplantation: An evidence-based review. *The Journal of Heart and Lung Transplantation*. 2013;32(9):849-60.
39. Niu D, Wei H-J, Lin L, George H, Wang T, Lee IH, et al. Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9. *Science (New York, NY)*. 2017.
40. Cypel M, Rubacha M, Yeung J, Hirayama S, Torbicki K, Madonik M, et al. Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2009;9(10):2262-9.

41. Cypel M, Yeung JC, Hirayama S, Rubacha M, Fischer S, Anraku M, et al. Technique for prolonged normothermic ex vivo lung perfusion. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2008;27(12):1319-25.
42. Ingemansson R, Eyjolfsson A, Mared L, Pierre L, Algotsson L, Ekmeahag B, et al. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. *The Annals of thoracic surgery*. 2009;87(1):255-60.
43. Steen S, Sjoberg T, Pierre L, Liao Q, Eriksson L, Algotsson L. Transplantation of lungs from a non-heart-beating donor. *Lancet (London, England)*. 2001;357(9259):825-9.
44. Bonenfant NR, Sokocevic D, Wagner DE, Borg ZD, Lathrop MJ, Lam YW, et al. The effects of storage and sterilization on de-cellularized and re-cellularized whole lung. *Biomaterials*. 2013;34(13):3231-45.
45. Matuska AM, McFetridge PS. The effect of terminal sterilization on structural and biophysical properties of a decellularized collagen-based scaffold; implications for stem cell adhesion. *Journal of biomedical materials research Part B, Applied biomaterials*. 2015;103(2):397-406.
46. Hodde J, Janis A, Ernst D, Zopf D, Sherman D, Johnson C. Effects of sterilization on an extracellular matrix scaffold: part I. Composition and matrix architecture. *Journal of materials science Materials in medicine*. 2007;18(4):537-43.
47. Balestrini JL, Liu A, Gard AL, Huie J, Blatt KM, Schwan J, et al. Sterilization of Lung Matrices by Supercritical Carbon Dioxide. *Tissue engineering Part C, Methods*. 2016;22(3):260-9.
48. Brown BN, Badylak SF. Extracellular matrix as an inductive scaffold for functional tissue reconstruction. *Translational research: the journal of laboratory and clinical medicine*. 2014;163(4):268-85.
49. Wolf MT, Vodovotz Y, Tottey S, Brown BN, Badylak SF. Predicting In Vivo Responses to Biomaterials via Combined In Vitro and In Silico Analysis. *Tissue engineering Part C, Methods*. 2015;21(2):148-59.
50. Petersen TH, Calle EA, Zhao L, Lee EJ, Gui L, Raredon MB, et al. Tissue-engineered lungs for in vivo implantation. *Science (New York, NY)*. 2010;329(5991):538-41.
51. Booth AJ, Hadley R, Cornett AM, Dreffe AA, Matthes SA, Tsui JL, et al. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. *American journal of respiratory and critical care medicine*. 2012;186(9):866-76.
52. Gilpin SE, Guyette JP, Gonzalez G, Ren X, Asara JM, Mathisen DJ, et al. Perfusion decellularization of human and porcine lungs: bringing the matrix to clinical scale. *The Journal of heart and lung transplantation*. 2014;33(3):298-308.
53. Gilpin SE, Ren X, Okamoto T, Guyette JP, Mou H, Rajagopal J, et al. Enhanced lung epithelial specification of human induced pluripotent stem cells on decellularized lung matrix. *The Annals of thoracic surgery*. 2014;98(5):1721-9; discussion 9.
54. Wallis JM, Borg ZD, Daly AB, Deng B, Ballif BA, Allen GB, et al. Comparative assessment of detergent-based protocols for mouse lung de-cellularization and re-cellularization. *Tissue engineering Part C, Methods*. 2012;18(6):420-32.
55. Petersen TH, Calle EA, Colehour MB, Niklason LE. Matrix composition and mechanics of decellularized lung scaffolds. *Cells, tissues, organs*. 2012;195(3):222-31.
56. Brown BN, Valentin JE, Stewart-Akers AM, McCabe GP, Badylak SF. Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. *Biomaterials*. 2009;30(8):1482-91.
57. Badylak SF, Gilbert TW. Immune Response to Biologic Scaffold Materials. *Seminars in immunology*. 2008;20(2):109-16.
58. Zvarova B, Uhl FE, Uriarte JJ, Borg ZD, Coffey AL, Bonenfant NR, et al. Residual Detergent Detection Method for Nondestructive Cytocompatibility Evaluation of Decellularized Whole Lung Scaffolds. *Tissue engineering Part C, Methods*. 2016;22(5):418-28.
59. Kawecki M, Łabuś W, Klama-Baryla A, Kitala D, Kraut M, Glik J, et al. A review of decellurization methods caused by an urgent need for quality control of cell-free extracellular matrix' scaffolds and their role in regenerative medicine. *Journal of Biomedical Materials Research Part B: Applied Biomaterials*. 2017:n/a-n/a.
60. Chen Y-W, Huang SX, de Carvalho ALRT, Ho S-H, Islam MN, Volpi S, et al. A three-dimensional model of human lung development and disease from pluripotent stem cells. *Nat Cell Biol*. 2017;19(5):542-9.

61. Huang SXL, Islam MN, O'Neill J, Hu Z, Yang Y-G, Chen Y-W, et al. Efficient generation of lung and airway epithelial cells from human pluripotent stem cells. *Nature Biotechnology*. 2014;32(1):84-91.
62. Longmire TA, Ikonomou L, Hawkins F, Christodoulou C, Cao Y, Jean JC, et al. Efficient derivation of purified lung and thyroid progenitors from embryonic stem cells. *Cell Stem Cell*. 2012;10(4):398-411.
63. Ghaedi M, Calle EA, Mendez JJ, Gard AL, Balestrini J, Booth A, et al. Human iPS cell-derived alveolar epithelium repopulates lung extracellular matrix. *The Journal of clinical investigation*. 2013;123(11):4950-62.
64. Wong AP, Bear CE, Chin S, Pasceri P, Thompson TO, Huan L-J, et al. Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. *Nature biotechnology*. 2012;30(9):876-82.
65. McCauley KB, Hawkins F, Serra M, Thomas DC, Jacob A, Kotton DN. Efficient Derivation of Functional Human Airway Epithelium from Pluripotent Stem Cells via Temporal Regulation of Wnt Signaling. *Cell Stem Cell*. 2017.
66. Gilpin SE, Charest JM, Ren X, Tapias LF, Wu T, Evangelista-Leite D, et al. Regenerative potential of human airway stem cells in lung epithelial engineering. *Biomaterials*. 2016;108:111-9.
67. Ren X, Moser PT, Gilpin SE, Okamoto T, Wu T, Tapias LF, et al. Engineering pulmonary vasculature in decellularized rat and human lungs. *Nat Biotechnology*. 2015;33(10):1097-102.
68. Shojaie S, Ermini L, Ackerley C, Wang J, Chin S, Yeganeh B, et al. Acellular Lung Scaffolds Direct Differentiation of Endoderm to Functional Airway Epithelial Cells: Requirement of Matrix-Bound HS Proteoglycans. *Stem Cell Reports*. 2015;4(3):419-30.
69. Ghaedi M, Le AV, Hatachi G, Beloiartsev A, Rocco K, Sivarapatna A, et al. Bioengineered lungs generated from human iPSCs-derived epithelial cells on native extracellular matrix. *Journal of tissue engineering and regenerative medicine*. 2018;12(3):e1623-e35.
70. Ott HC, Clippinger B, Conrad C, Schuetz C, Pomerantseva I, Ikonomou L, et al. Regeneration and orthotopic transplantation of a bioartificial lung. *Nature Medicine*. 2010;16(8):927-33.
71. Song JJ, Kim SS, Liu Z, Madsen JC, Mathisen DJ, Vacanti JP, et al. Enhanced in vivo function of bioartificial lungs in rats. *The Annals of thoracic surgery*. 2011;92(3):998-1005; discussion -6.
72. Seif-Naraghi SB, Horn D, Schup-Magoffin PA, Madani MM, Christman KL. Patient-to-patient variability in autologous pericardial matrix scaffolds for cardiac repair. *Journal of Cardiovascular Translational Research*. 2011;4(5):545-56.
73. Londono R, Dziki JL, Haljasmaa E, Turner NJ, Leifer CA, Badylak SF. The effect of cell debris within biologic scaffolds upon the macrophage response. *Journal of biomedical materials research Part A*. 2017;105(8):2109-18.
74. Crowley C, Klanrit P, Butler CR, Varanou A, Plate M, Hynds RE, et al. Surface modification of a POSS-nanocomposite material to enhance cellular integration of a synthetic bioscaffold. *Biomaterials*. 2016;83:283-93.
75. Hinderer S, Schesny M, Bayrak A, Ibold B, Hampel M, Walles T, et al. Engineering of fibrillar decorin matrices for a tissue-engineered trachea. *Biomaterials*. 2012;33(21):5259-66.
76. Crowley C, Birchall M, Seifalian AM. Trachea transplantation: from laboratory to patient. *Journal of tissue engineering and regenerative medicine*. 2015;9(4):357-67.
77. Jungebluth P, Alici E, Baiguera S, Blomberg P, Bozóky B, Crowley C, et al. Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study. *The Lancet*. 2011;378(9808):1997-2004.
78. Teoh GZ, Crowley C, Birchall MA, Seifalian AM. Development of resorbable nanocomposite tracheal and bronchial scaffolds for paediatric applications. *The British journal of surgery*. 2015;102(2):e140-50.
79. Chang JW, Park SA, Park JK, Choi JW, Kim YS, Shin YS, et al. Tissue-engineered tracheal reconstruction using three-dimensionally printed artificial tracheal graft: preliminary report. *Artificial organs*. 2014;38(6):E95-e105.
80. Jungebluth P, Haag JC, Sjoqvist S, Gustafsson Y. Tracheal tissue engineering in rats. *Nature Protocols*. 2014;9(9):2164-79.
81. Cortiella J, Nichols JE, Kojima K, Bonassar LJ, Dargon P, Roy AK, et al. Tissue-engineered lung: an in vivo and in vitro comparison of polyglycolic acid and pluronic F-127 hydrogel/somatic lung progenitor cell constructs to support tissue growth. *Tissue engineering Part A*. 2006;12(5):1213-25.
82. Mondrinos MJ, Koutzaki S, Jiwanmall E, Li M, Dechadarevian JP, Lelkes PI, et al. Engineering three-dimensional pulmonary tissue constructs. *Tissue engineering*. 2006;12(4):717-28.

83. Weibel ER. Lung morphometry: the link between structure and function. *Cell and Tissue Research*. 2017;367(3):413-26.
84. Ling TY, Liu YL, Huang YK, Gu SY, Chen HK, Ho CC, et al. Differentiation of lung stem/progenitor cells into alveolar pneumocytes and induction of angiogenesis within a 3D gelatin--microbubble scaffold. *Biomaterials*. 2014;35(22):5660-9.
85. Andrade CF, Wong AP, Waddell TK, Keshavjee S, Liu M. Cell-based tissue engineering for lung regeneration. *American Journal of Physiology-Lung Cellular and Molecular Physiology*. 2007;292(2):L510-L8.
86. Singh D, Zo SM, Kumar A, Han SS. Engineering three-dimensional macroporous hydroxyethyl methacrylate-alginate-gelatin cryogel for growth and proliferation of lung epithelial cells. *Journal of biomaterials science Polymer edition*. 2013;24(11):1343-59.
87. Lewis KJR, Hall JK, Kiyotake EA, Christensen T, Balasubramaniam V, Anseth KS. Epithelial-mesenchymal crosstalk influences cellular behavior in a 3D alveolus-fibroblast model system. *Biomaterials*. 2018;155:124-34.
88. Lewis KJR, Tibbitt MW, Zhao Y, Branchfield K, Sun X, Balasubramaniam V, et al. In vitro model alveoli from photodegradable microsphere templates. *Biomaterials science*. 2015;3(6):821-32.
89. Wilkinson DC, Alva-Ornelas JA, Sucre JM, Vijayaraj P, Durra A, Richardson W, et al. Development of a Three-Dimensional Bioengineering Technology to Generate Lung Tissue for Personalized Disease Modeling. *Stem cells translational medicine*. 2017;6(2):622-33.
90. Nematollahi Z, Tafazzoli-Shadpour M, Zamanian A, Seyedsalehi A, Mohammad-Behgam S, Ghorbani F, et al. Fabrication of Chitosan Silk-based Tracheal Scaffold Using Freeze-Casting Method. *Iranian biomedical journal*. 2017.
91. Lee VK, Kim DY, Ngo H, Lee Y, Seo L, Yoo SS, et al. Creating perfused functional vascular channels using 3D bio-printing technology. *Biomaterials*. 2014;35(28):8092-102.
92. Ercolani E, Del Gaudio C, Bianco A. Vascular tissue engineering of small-diameter blood vessels: reviewing the electrospinning approach. *Journal of tissue engineering and regenerative medicine*. 2015;9(8):861-88.
93. Powell HM, Boyce ST. Engineered human skin fabricated using electrospun collagen-PCL blends: morphogenesis and mechanical properties. *Tissue Engineering Part A*. 2009;15(8):2177-87.
94. Bhattacharjee T, Zehnder SM, Rowe KG, Jain S, Nixon RM, Sawyer WG, et al. Writing in the granular gel medium. *Science advances*. 2015;1(8):e1500655.
95. Hinton TJ, Jallerat Q, Palchesko RN, Park JH, Grodzicki MS, Shue H-J, et al. Three-dimensional printing of complex biological structures by freeform reversible embedding of suspended hydrogels. *Science advances*. 2015;1(9):e1500758.
96. Feinberg AW, Miller JS. Progress in three-dimensional bioprinting. *MRS Bulletin*. 2017;42(8):557-62.
97. Zhu W, Qu X, Zhu J, Ma X, Patel S, Liu J, et al. Direct 3D bioprinting of prevascularized tissue constructs with complex microarchitecture. *Biomaterials*. 2017;124:106-15.
98. Kolesky DB, Homan KA, Skylar-Scott MA, Lewis JA. Three-dimensional bioprinting of thick vascularized tissues. *Proceedings of the National Academy of Sciences of the United States of America*. 2016;113(12):3179-84.
99. Hansen CJ, Saksena R, Kolesky DB, Vericella JJ, Kranz SJ, Muldowney GP, et al. High-throughput printing via microvascular multinozzle arrays. *Advanced materials (Deerfield Beach, Fla)*. 2013;25(1):96-102.
100. Pratt AB, Weber FE, Schmoekel HG, Muller R, Hubbell JA. Synthetic extracellular matrices for in situ tissue engineering. *Biotechnology and bioengineering*. 2004;86(1):27-36.
101. Morrison RJ, Hollister SJ, Niedner MF, Mahani MG, Park AH, Mehta DK, et al. Mitigation of tracheobronchomalacia with 3D-printed personalized medical devices in pediatric patients. *Science Translational Medicine*. 2015;7(285):285ra64-ra64.
102. Zopf DA, Hollister SJ, Nelson ME, Ohye RG, Green GE. Bioresorbable airway splint created with a three-dimensional printer. *The New England journal of medicine*. 2013;368(21):2043-5.
103. Taniguchi D, Matsumoto K, Tsuchiya T, Machino R, Takeoka Y, Elgalad A, et al. Scaffold-free trachea regeneration by tissue engineering with bio-3D printing. *Interactive cardiovascular and thoracic surgery*. 2018.
104. Cubo N, Garcia M, Del Canizo JF, Velasco D, Jorcano JL. 3D bioprinting of functional human skin: production and in vivo analysis. *Biofabrication*. 2016;9(1):015006.

105. Cui X, Breitenkamp K, Finn MG, Lotz M, D'Lima DD. Direct human cartilage repair using three-dimensional bioprinting technology. *Tissue Engineering Part A*. 2012;18(11-12):1304-12.
106. Duan B, Hockaday LA, Kang KH, Butcher JT. 3D bioprinting of heterogeneous aortic valve conduits with alginate/gelatin hydrogels. *Journal of biomedical materials research Part A*. 2013;101(5):1255-64.
107. Norotte C, Marga FS, Niklason LE, Forgacs G. Scaffold-free vascular tissue engineering using bioprinting. *Biomaterials*. 2009;30(30):5910-7.
108. Polak DJ. The use of stem cells to repair the injured lung. *British medical bulletin*. 2011;99:189-97.
109. Butler CR, Hynds RE. Rapid Expansion of Human Epithelial Stem Cells Suitable for Airway Tissue Engineering. *American journal of respiratory and critical care medicine*. 2016;194(2):156-68.
110. Naikawadi RP, Disayabutr S, Mallavia B, Donne ML, Green G, La JL, et al. Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis. *JCI Insight*. 2016;1(14):e86704.
111. Shaykhiev R, Wang R, Zwick RK, Hackett NR, Leung R, Moore MAS, et al. Airway Basal Cells of Healthy Smokers Express an Embryonic Stem Cell Signature Relevant to Lung Cancer. *Stem cells*. 2013;31(9):1992-2002.
112. Gentzsch M, Boyles SE, Cheluvharaju C, Chaudhry IG, Quinney NL, Cho C, et al. Pharmacological Rescue of Conditionally Reprogrammed Cystic Fibrosis Bronchial Epithelial Cells. *American journal of respiratory cell and molecular biology*. 2017;56(5):568-74.
113. Firth AL, Menon T, Parker GS, Qualls SJ, Lewis BM, Ke E, et al. Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated From Patient iPSCs. *Cell reports*. 2015;12(9):1385-90.
114. Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, et al. Epigenetic memory in induced pluripotent stem cells. *Nature*. 2010;467(7313):285-90.
115. Firth AL, Dargitz CT, Qualls SJ, Menon T, Wright R, Singer O, et al. Generation of multiciliated cells in functional airway epithelia from human induced pluripotent stem cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(17):E1723-E30.
116. Hawkins F, Kramer P, Jacob A, Driver I, Thomas DC, McCauley KB, et al. Prospective isolation of NKX2-1-expressing human lung progenitors derived from pluripotent stem cells. *The Journal of clinical investigation*. 2017;127(6):2277-94.
117. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006;126(4):663-76.
118. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. *Science (New York, NY)*. 1998;282(5391):1145-7.
119. Raredon MSB, Ghaedi M, Calle EA, Niklason LE. A Rotating Bioreactor for Scalable Culture and Differentiation of Respiratory Epithelium. *Cell Medicine*. 2015;7(3):109-21.
120. Kempf H, Kropp C, Olmer R, Martin U, Zweigerdt R. Cardiac differentiation of human pluripotent stem cells in scalable suspension culture. *Nature Protocols*. 2015;10(9):1345-61.
121. Olmer R, Lange A, Selzer S, Kasper C, Haverich A, Martin U, et al. Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors. *Tissue engineering Part C, Methods*. 2012;18(10):772-84.
122. Cortiella J, Nichols JE, Kojima K, Bonassar LJ, Dargon P, Roy AK, et al. Tissue-engineered lung: an in vivo and in vitro comparison of polyglycolic acid and pluronic F-127 hydrogel/somatic lung progenitor cell constructs to support tissue growth. *Tissue engineering*. 2006;12(5):1213-25.
123. Lin YM, Boccaccini AR, Polak JM, Bishop AE, Maquet V. Biocompatibility of poly-DL-lactic acid (PDLLA) for lung tissue engineering. *Journal of biomaterials applications*. 2006;21(2):109-18.
124. Kuttan R, Spall RD, Duhamel RC, Sipes IG, Meezan E, Brendel K. Preparation and composition of alveolar extracellular matrix and incorporated basement membrane. *Lung*. 1981;159(6):333-45.
125. Lwebuga-Mukasa JS, Ingbar DH, Madri JA. Repopulation of a human alveolar matrix by adult rat type II pneumocytes in vitro. A novel system for type II pneumocyte culture. *Experimental cell research*. 1986;162(2):423-35.
126. Petersen TH, Calle EA, Zhao L, Lee EJ, Gui L, Raredon MB, et al. Tissue-Engineered Lungs for in Vivo Implantation. *Science (New York, NY)*. 2010;329(5991):538-41.
127. Shamis Y, Hasson E, Soroker A, Bassat E, Shimoni Y, Ziv T, et al. Organ-specific scaffolds for in vitro expansion, differentiation, and organization of primary lung cells. *Tissue engineering Part C, Methods*. 2011;17(8):861-70.

128. Sokocevic D, Bonenfant NR, Wagner DE, Borg ZD, Lathrop MJ, Lam YW, et al. The effect of age and emphysematous and fibrotic injury on the re-cellularization of de-cellularized lungs. *Biomaterials*. 2013;34(13):3256-69.
129. Pouliot RA, Link PA, Mikhael NS, Schneck MB, Valentine MS, Kamga Gninzeko FJ, et al. Development and characterization of a naturally derived lung extracellular matrix hydrogel. *Journal of biomedical materials research Part A*. 2016;104(8):1922-35.
130. Mondrinos MJ, Koutzaki SH, Poblete HM, Crisanti MC, Lelkes PI, Finck CM. In vivo pulmonary tissue engineering: contribution of donor-derived endothelial cells to construct vascularization. *Tissue engineering Part A*. 2008;14(3):361-8.
131. Zhang W-J, Lin Q-X, Zhang Y, Liu C-T, Qiu L-Y, Wang H-B, et al. The reconstruction of lung alveolus-like structure in collagen-matrigel/microcapsules scaffolds in vitro. *Journal of Cellular and Molecular Medicine*. 2011;15(9):1878-86.
132. Ghorbani F, Moradi L, Shadmehr MB, Bonakdar S, Droodinia A, Safshekan F. In-vivo characterization of a 3D hybrid scaffold based on PCL/decellularized aorta for tracheal tissue engineering. *Materials science & engineering C, Materials for biological applications*. 2017;81:74-83.
133. Stabler CT, Caires LC, Mondrinos MJ, Marcinkiewicz C, Lazarovici P, Wolfson MR, et al. Enhanced Re-Endothelialization of Decellularized Rat Lungs. *Tissue engineering Part C, Methods*. 2016;22(5):439-50.
134. Scarritt ME, Pashos NC, Motherwell JM, Eagle ZR, Burkett BJ, Gregory AN, et al. Re-endothelialization of rat lung scaffolds through passive, gravity-driven seeding of segment-specific pulmonary endothelial cells. *Journal of tissue engineering and regenerative medicine*. 2018;12(2):e786-e806.
135. Scarritt ME, Bonvillain RW, Burkett BJ, Wang G, Glotser EY, Zhang Q, et al. Hypertensive Rat Lungs Retain Hallmarks of Vascular Disease upon Decellularization but Support the Growth of Mesenchymal Stem Cells. *Tissue engineering Part A*. 2014;20(9-10):1426-43.
136. Panoskaltsis-Mortari A. Bioreactor Development for Lung Tissue Engineering. *Current transplantation reports*. 2015;2(1):90-7.
137. Ghaedi M, Mendez JJ, Bove PF, Sivarapatna A, Raredon MS, Niklason LE. Alveolar epithelial differentiation of human induced pluripotent stem cells in a rotating bioreactor. *Biomaterials*. 2014;35(2):699-710.
138. Khalpey Z, Qu N, Hemphill C, Louis AV, Ferng AS, Son TG, et al. Rapid porcine lung decellularization using a novel organ regenerative control acquisition bioreactor. *ASAIO Journal*. 2015;61(1):71-7.
139. Warnecke G, Moradiellos J, Tudorache I, Kühn C, Avsar M, Wiegmann B, et al. Normothermic perfusion of donor lungs for preservation and assessment with the Organ Care System Lung before bilateral transplantation: a pilot study of 12 patients. *The Lancet*. 2012;380(9856):1851-8.
140. Spratt JR, Mattison LM, Iazzo PA, Meyer C, Iles TL, Panoskaltsis-Mortari A, et al. Lung Transplantation from DCD Donors After Prolonged Normothermic Portable EVLP. *The Journal of Heart and Lung Transplantation*. 2017;36(4):S312.
141. Spratt JR, Mattison LM, Kerns NK, Huddleston SJ, Meyer L, Loo G, et al. Prolonged Preservation and Evaluation of Human Lungs With Portable Normothermic EVLP. *The Journal of Heart and Lung Transplantation*. 2018;37(4):S242.
142. Miller C, George S, Niklason L. Developing a tissue-engineered model of the human bronchiole. *J Tissue Eng Regen Med*. 2010;4(8):619-27.
143. Delaere P, Vranckx J, Verleden G, De Leyn P, Van Raemdonck D. Tracheal allotransplantation after withdrawal of immunosuppressive therapy. *N Engl J Med*. 2010;362(2):138-45.
144. Delaere PR, Vranckx JJ, Den Hondt M. Tracheal allograft after withdrawal of immunosuppressive therapy. *N Engl J Med*. 2014;370(16):1568-70.
145. Kemter E, Wolf E. Pigs pave a way to de novo formation of functional human kidneys. *Proceedings of the National Academy of Sciences*. 2015;112(42):12905-6.
146. Garry MG, Garry DJ. Humanized organs in gene-edited animals. *Regenerative medicine*. 2016;11(7):617-9.
147. Elliott MJ, Butler CR, Varanou-Jenkins A, Partington L, Carvalho C, Samuel E, et al. Tracheal Replacement Therapy with a Stem Cell-Seeded Graft: Lessons from Compassionate Use Application of a GMP-Compliant Tissue-Engineered Medicine. *Stem cells translational medicine*. 2017;6(6):1458-64.


148. Etienne H, Fabre D, Gomez Caro A, Kolb F, Mussot S, Mercier O, et al. Tracheal replacement. *European Respiratory Journal*. 2018;51(2).
149. Ikonomou L, Freishtat RJ, Wagner DE, Panoskaltsis-Mortari A, Weiss DJ. The Global Emergence of Unregulated Stem Cell Treatments for Respiratory Diseases. Professional Societies Need to Act. *Annals of the American Thoracic Society*. 2016;13(8):1205-7.
150. Anderson R, O'Hare M, Balls M, Brady M, Brahams D, Burt A, et al. The Availability of Human Tissue for Biomedical Research: The Report and Recommendations of the ECVAM Workshop 32. *Alternatives to laboratory animals : ATLA*. 1998;26(6):763-77.
151. Beier K, Schnorrer S, Hoppe N, Lenk C. The ethical and legal regulation of human tissue and biobank research in Europe - Proceedings of the Tiss.EU Project: Universitätsverlag Göttingen; 2011.
152. Medicine Io, Council NR. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Berger AC, Beachy SH, Olson S, editors. Washington, DC: The National Academies Press; 2014. 108 p.
153. Machuca TN, Mercier O, Collaud S, Linacre V, Krueger T, Azad S, et al. Outcomes of Lung Transplantation Using Donation after Cardiac Death Donors: Should We Use Ex Vivo Lung Perfusion? *The Journal of Heart and Lung Transplantation*. 2014;33(4):S272.
154. Mao AS, Mooney DJ. Regenerative medicine: Current therapies and future directions. *Proceedings of the National Academy of Sciences of the United States of America*. 2015;112(47):14452-9.
155. Kaplan AV, Baim DS, Smith JJ, Feigal DA, Simons M, Jefferys D, et al. Medical Device Development: From Prototype to Regulatory Approval. *Circulation*. 2004;109(25):3068-72.
156. Konomi K, Tobita M, Kimura K, Sato D. New Japanese initiatives on stem cell therapies. *Cell Stem Cell*. 2015;16(4):350-2.
157. Dorrello NV, Guenthart BA, O'Neill JD, Kim J, Cunningham K, Chen Y-W, et al. Functional vascularized lung grafts for lung bioengineering. *Science advances*. 2017;3(8):e1700521.
158. Chang WG, Niklason LE. A short discourse on vascular tissue engineering. *npj Regenerative Medicine*. 2017;2(1):7.
159. Fernandez-Moure JS, Van Eps JL, Rhudy JR, Cabrera FJ, Acharya GS, Tasciotti E, et al. Porcine acellular lung matrix for wound healing and abdominal wall reconstruction: A pilot study. *Journal of Tissue Engineering*. 2016;7:2041731415626018.
160. Tsuchiya T, Balestrini JL, Mendez J, Calle EA, Zhao L, Niklason LE. Influence of pH on Extracellular Matrix Preservation During Lung Decellularization. *Tissue engineering Part C, Methods*. 2014;20(12):1028-36.
161. Zhou Y, Peng H, Sun H, Peng X, Tang C, Gan Y, et al. Chitinase 3-like 1 Suppresses Injury and Promotes Fibroproliferative Responses in Mammalian Lung Fibrosis. *Science translational medicine*. 2014;6(240):240ra76-ra76.
162. Lechner AJ, Driver IH, Lee J, Conroy CM, Nagle A, Locksley RM, et al. Recruited Monocytes and Type 2 Immunity Promote Lung Regeneration following Pneumonectomy. *Cell Stem Cell*. 2017;21(1):120-34.e7.
163. Rosengard BR, Feng S, Alfrey EJ, Zaroff JG, Emond JC, Henry ML, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2002;2(8):701-11.
164. Raemdonck D, Neyrinck A, Cypel M, Keshavjee S. Ex-vivo lung perfusion. *Transplant International*. 2015;28(6):643-56.
165. Lindstedt S, Eyjolfsson A, Koul B, Wierup P, Pierre L, Gustafsson R, et al. How to recondition ex vivo initially rejected donor lungs for clinical transplantation: clinical experience from lund university hospital. *Journal of transplantation*. 2011;2011:754383.
166. Lefrançois E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. *Nature*. 2017;544(7648):105-9.
167. Morales-Nebreda L, Misharin AV, Perlman H, Budinger GRS. The heterogeneity of lung macrophages in the susceptibility to disease. *European Respiratory Review*. 2015;24(137):505-9.

168. Fakhro M, Ingemansson R, Skog I, Algotsson L, Hansson L, Koul B, et al. 25-year follow-up after lung transplantation at Lund University Hospital in Sweden: superior results obtained for patients with cystic fibrosis. *Interactive cardiovascular and thoracic surgery*. 2016;23(1):65-73.
169. Sa S, Gu M, Chappell J, Shao NY, Ameen M, Elliott KA, et al. Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity. *American journal of respiratory and critical care medicine*. 2017;195(7):930-41.
170. Sato M, Okada Y, Oto T, Minami M, Shiraishi T, Nagayasu T, et al. Registry of the Japanese Society of Lung and Heart–Lung Transplantation: official Japanese lung transplantation report, 2014. *General Thoracic and Cardiovascular Surgery*. 2014;62(10):594-601.
171. Takahashi K, Chen F, Ikeda T, Doi H, Nakamura H, Yanagi S, et al. Single-Lobe Lung Transplantation for Rapidly Deteriorating Pulmonary Venocclusive Disease. *The Annals of thoracic surgery*. 2013;95(2):689-91.
172. Wagner DE, Fenn SL, Bonenfant NR, Marks ER, Borg Z, Saunders P, et al. Design and Synthesis of an Artificial Pulmonary Pleura for High Throughput Studies in Acellular Human Lungs. *Cellular and molecular bioengineering*. 2014;7(2):184-95.
173. Fenn SL, Charron PN, Oldinski RA. Anticancer Therapeutic Alginate-Based Tissue Sealants for Lung Repair. *ACS Applied Materials & Interfaces*. 2017;9(28):23409-19.


Figure Legends

Figure 1. Lung bioengineering approaches. In most approaches, a lung scaffold is seeded with autologous or allogeneic cells for bioengineering a lung. The cells can be expanded to appropriate numbers in bioreactors for cell expansion. Different lung scaffolds have been explored including decellularised scaffolds and synthetic scaffolds. An emerging idea is the use of hybrid scaffolds which combine biologic materials such as ECM components with synthetic scaffolds in order to create a hybrid lung scaffold. Bioreactors for organ culture can then be used to mature and evaluate the repopulated lung scaffold before lung transplantation.


Figure 2. Recapitulating the complexity of the lung architecture from proximal (trachea) to distal (bronchi and alveoli). The lung architecture varies dramatically within the lung: moving from proximal to distal, the resolution required to mimic the native structures is higher. To date, biologic scaffolds are the only scaffolds that have a resolution which mimics that of the native lung across all length scales. H&E staining histology, transmission electron microscopy (TEM) and scanning electron microscopy (SEM) images from proximal and distal native lung tissue are shown. The bronchi TEM inset shows a mucous membrane of small human bronchus. *A*: thin section showing ciliated cell (*CC*) with cilia (*C*) and microvilli, goblet cell (*GC*) with apical mucous plug (*MU*), basal cell (*BC*), fibers and fibroblasts (*FB*) in connective tissue and macrophages (*MP*). *B*: SEM micrograph of epithelial surface showing ciliary tufts (*C*) and mucous plug (*MU*) of goblet cell in process of extrusion. The distal lung inset shows the structure of the alveolar septum in human lungs in a TEM and SEM micrograph. Septal fibroblast (*FB*), capillary endothelium (*EN*), alveolar epithelium (*EP*), fiber strands (*F*). H&E histology images scale bars= 100µm, bronchi TEM image *A* scale bar = 5 µm, bronchi SEM image *B* scale bar= 10µm, distal lung TEM scale bar= 2 µm, distal lung SEM scale bar= 10µm. Electron microscopy inset images reproduced with permission of the rights holder Ewald R. Weibel, Lung Cell Biology, Comprehensive Physiology 2011.







distal lung



bronchi



trachea



scaffold	resolution
biologic	cm - nm
synthetic	cm - μ m
hybrid	cm - μ m

resolution needed

anatomic size



nm

distal

μ m

proximal

cm